Traws Pharma, Inc. Cash Flow Statement
TRAW|12 years of annual SEC 10-K data (FY2013-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 12 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$30M
FY2024
Free Cash Flow
-$30M
FY2024
Capital Expenditures
$14,000
Cash used for long-term assets
Dividends Paid
N/A
FY2024
Traws Pharma, Inc. used $30M in operating cash flow and negative free cash flow of $30M in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Negative shareholders equity: Liabilities exceed assets
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$166.5M | -$19.0M | -$16.2M | -$25.2M | -$21.5M | -$20.6M | -$24.1M | -$19.7M | -$24.0M | -$63.7M | -$29.9M | -$26.3M |
| Depreciation & Amortization | $12.0K | $14.0K | $14.0K | $13.0K | $14.0K | $55.0K | $88.0K | $96.0K | $150.0K | $434.0K | $319.0K | $316.0K |
| Operating Cash Flow | -$29.8M | -$16.3M | -$19.5M | -$23.1M | -$20.8M | -$22.7M | -$23.8M | -$15.8M | -$31.2M | -$57.6M | $1.6M | -$14.2M |
| Capital Expenditures | $14.0K | $14.0K | - | $15.0K | $55.0K | $55.0K | - | - | - | $228.0K | $279.0K | $256.0K |
| Free Cash Flow | -$29.8M | -$16.3M | - | -$23.1M | -$20.9M | -$22.8M | - | - | - | -$57.9M | $1.4M | -$14.4M |
| FCF Margin | -13188.5% | -7215.9% | - | -9995.7% | -956.8% | -1852.7% | - | - | - | -7234.5% | 2.9% | -970.2% |